For the quarter ending 2025-09-30, TTRX had $2,233,557 increase in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 |
|---|---|
| Net loss attributable to common stockholders | -3,473,150 |
| Amortization expense | 38,591 |
| Stock-based compensation expense | 162,865 |
| Common stock issued in exchange for services | 250,000 |
| Non-cash operating lease effect | 1,165 |
| Prepaids and other current assets | -36,742 |
| Accounts payable and accrued expenses | 1,597,153 |
| Net cash used in operating activities | -1,386,634 |
| Purchases of intangible assets | 121,545 |
| Net cash used in investing activities | -121,545 |
| Proceeds from issuance of common stock, net of issuance costs | 3,741,736 |
| Net cash provided by financing activities | 3,741,736 |
| Net increase (decrease) in cash and cash equivalents | 2,233,557 |
| Cash and cash equivalents at beginning of period | 872,599 |
| Cash and cash equivalents at end of period | 3,106,156 |
Turn Therapeutics Inc. (TTRX)
Turn Therapeutics Inc. (TTRX)